Skip to content

Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 1

Clinical Comparison of 2 Daily Disposable Contact Lenses - Pilot Study 1

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04527978
Enrollment
56
Registered
2020-08-27
Start date
2020-09-15
Completion date
2020-11-06
Last updated
2021-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors, Myopia

Keywords

Daily disposable contact lenses

Brief summary

The primary objective of this study is to evaluate the overall performance of PRECISION1 contact lenses when compared to Biotrue ONEday contact lenses.

Detailed description

Subjects are expected to attend 3 study visits and wear the PRECISION1 and Biotrue ONEday study lenses in a crossover design for approximately 8 days of exposure to each study lens type. The expected duration of subject participation is up to 22 days.

Interventions

Spherical soft contact lenses for daily disposable wear

Spherical soft contact lenses for daily disposable wear

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * Subject must be able to understand and must sign an Institution Review Board (IRB) approved Informed Consent Form. * Successful wear of spherical soft contact lenses in both eyes for a minimum of 5 days per week and 10 hours per day during the past 3 months. * Willing to wear contact lenses for at least 16 hours per day on one of the days with each lens type. * Other protocol-specified inclusion criteria may apply. Key

Exclusion criteria

* Any ocular condition that contraindicates contact lens wear. * Previous or current habitual wearer of PRECISION1, Biotrue ONEday, or DAILIES TOTAL1 contact lenses. * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
Distance Visual Acuity (VA) With Study LensesDay 8 (-0/+3 days) after 10 (-2/+6) hours of wear, each study lens typeDistance VA was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity. No formal hypothesis was predefined for the primary endpoint. No inferential testing was performed.

Countries

United States

Participant flow

Recruitment details

Subjects were recruited from 4 investigative sites located in the United States.

Pre-assignment details

Of the 56 subjects enrolled in the study, 1 subject was discontinued after randomization and prior to exposure to the study lenses. This reporting group includes all randomized and exposed subjects (55).

Participants by arm

ArmCount
PRECISION1, Then Biotrue ONEday
Verofilcon A contact lenses worn first, with nesofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
27
Biotrue ONEday, Then PRECISION1
Nesofilcon A contact lenses worn first, with verofilcon A contact lenses worn second, as randomized. Each study lens type was worn bilaterally (in both eyes) for 8 -0/+3 days in a daily disposable modality.
28
Total55

Withdrawals & dropouts

PeriodReasonFG000FG001
First Wear Period (8 -0/+3 Days)Adverse Event10

Baseline characteristics

CharacteristicPRECISION1, Then Biotrue ONEdayTotalBiotrue ONEday, Then PRECISION1
Age, Continuous33.7 years
STANDARD_DEVIATION 6.3
34.0 years
STANDARD_DEVIATION 7.7
34.3 years
STANDARD_DEVIATION 8.9
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants4 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
24 Participants51 Participants27 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
1 Participants2 Participants1 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants1 Participants0 Participants
Race (NIH/OMB)
White
25 Participants51 Participants26 Participants
Region of Enrollment
United States
27 participants55 participants28 participants
Sex: Female, Male
Female
20 Participants45 Participants25 Participants
Sex: Female, Male
Male
7 Participants10 Participants3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
deaths
Total, all-cause mortality
0 / 550 / 1100 / 550 / 1080 / 54
other
Total, other adverse events
0 / 550 / 1100 / 550 / 1080 / 54
serious
Total, serious adverse events
0 / 550 / 1100 / 550 / 1080 / 54

Outcome results

Primary

Distance Visual Acuity (VA) With Study Lenses

Distance VA was assessed with study lenses in place. VA was collected for each eye separately using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity. No formal hypothesis was predefined for the primary endpoint. No inferential testing was performed.

Time frame: Day 8 (-0/+3 days) after 10 (-2/+6) hours of wear, each study lens type

Population: Safety Analysis Set with non-missing response

ArmMeasureValue (MEAN)Dispersion
PRECISION1Distance Visual Acuity (VA) With Study Lenses-0.13 logMARStandard Deviation 0.08
Biotrue ONEdayDistance Visual Acuity (VA) With Study Lenses-0.12 logMARStandard Deviation 0.08

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026